PsychedelicNewsBreaks

FridayMay 16, 2025 9:00 am

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup 

NRx Pharmaceuticals (NASDAQ: NRXP) reported a Q1 2025 net loss of $5.5 million, down from $6.5 million in the same period last year, with operating losses narrowing to $3.8 million. The company advanced regulatory and commercial milestones for its two lead programs: NRX-100, a preservative-free IV ketamine formulation for suicidal depression now supported by an NDA fee waiver and new patent filing; and NRX-101, an oral treatment for bipolar depression with a PDUFA date anticipated before year-end. Subsidiary HOPE Therapeutics also gained momentum with $10.3 million in new acquisition funding to support a national psychiatry clinic rollup. NRx ended the…

Continue Reading

ThursdayMay 15, 2025 12:30 pm

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Secures $7.8M to Launch Clinic Rollup Strategy

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a term sheet with Universal Capital, LLC for $7.8 million in acquisition funding to support the rollout of its national interventional psychiatry clinic network. Combined with previously announced investments, HOPE now has $10.3 million in capital to execute initial acquisitions of Dura Medical, Kadima, and NeuroSpa. These clinics offer neuroplastic treatments such as ketamine and transcranial magnetic stimulation to treat severe depression and PTSD, with current contracts in place to serve veterans through the VA. Universal Capital expects to participate in future funding rounds as HOPE…

Continue Reading

WednesdayMay 14, 2025 3:41 pm

PsychedelicNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE’s Strategic Kadima Agreement

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is scheduled to report its first quarter 2025 financial results after the market closes on Thursday, May 15. A conference call and webcast will follow at 4:30 p.m. ET, accessible via the company’s investor relations site or by dialing +1-800-717-1738 (U.S.) or +1-646-307-1865 (international).  The earnings update comes shortly after news that NRx’s wholly owned subsidiary, HOPE Therapeutics, signed a definitive agreement to acquire Kadima Neuropsychiatry Institute in La Jolla, California. Kadima is a profitable clinic and leader in psychedelic and neuroplastic research, offering treatments for suicidal depression, PTSD and other CNS conditions. It is…

Continue Reading

TuesdayMay 13, 2025 9:00 am

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a definitive agreement to acquire the Kadima Neuropsychiatry Institute. Kadima, a leading California clinic for interventional psychiatry, offers treatments such as ketamine, Spravato, transcranial magnetic stimulation (TMS), and medication management for CNS disorders including suicidal depression and PTSD. The clinic is profitable and expected to serve as the clinical model for future HOPE clinics. Dr. David Feifel, Kadima’s founder and a nationally recognized leader in interventional psychiatry, will join HOPE as its first Chief Medical Innovation Officer following the closing of the acquisition, which remains subject…

Continue Reading

FridayMay 17, 2024 3:10 pm

PsychedelicNewsBreaks – Psychedelic Therapeutics and Drug Development Conference Partners with PsychedelicNewsWire as Official Media Sponsor

The Psychedelic Therapeutics and Drug Development announced that PsychedelicNewsWire (“PNW), a specialized communications platform for the psychedelics sector and one of more than 60 brands powered by IBN (“InvestorBrandNetwork”), will be the official media sponsor for this month’s conference. The fourth annual Psychedelic Therapeutics and Drug Development Conference is scheduled for May 23–24, 2024, in Boston. Hosted by Arrowhead SciTech Conferences & Events, the conference is focused on research and development of psychedelics in the healthcare space. The conference agenda features presentations by the world’s leading researchers and thought leaders in academia, industry, the nonprofit sector and government, with an objective to…

Continue Reading

ThursdayMay 16, 2024 2:01 pm

PsychedelicNewsBreaks – 4th Annual Psychedelic Therapeutics and Drug Development Conference to Bridge Gaps in Research and Development of Therapeutic Psychedelics

Arrowhead Sci-Tech Conferences and Events today announced the 4th Annual Psychedelic Therapeutics and Drug Development Conference, the flagship event for research and therapeutics development in the psychedelics space. The event will be held May 23-24, 2024, at the iconic Revere Hotel Boston Common in Boston, MA. The two-day event is expected to attract the world’s leading researchers and thought leaders in academia, industry, the non-profit sector, and government that aim to bridge gaps in the research and development (“R&D”) sphere related to therapeutic psychedelics. The conference will focus on the R&D of psychedelics for various health conditions with considerable unmet…

Continue Reading

TuesdayApr 30, 2024 12:59 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Conduct Clinical Trial to Assess Safety, Efficacy of unbuzzd(TM)

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has entered into agreement with Florida-based Applied Science and Performance Institute (“ASPI”). The agreement outlines plans to conduct a randomized, double-blind, placebo-controlled crossover study designed to assess the safety and efficacy of FSD Pharma’s unbuzzd(TM). The study will be conducted with healthy volunteers in an induced state of alcohol intoxication. A unique dietary supplement with natural ingredients, vitamins and Generally Recognized as Safe (“GRAS”) ingredients, unbuzzd exhibits potential…

Continue Reading

ThursdayApr 25, 2024 2:43 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation at the 27th Annual Milken Institute Global Conference

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company developing new and innovative next-generation psychedelic-based treatment options, is announcing its participation at the 27th Annual Milken Institute Global Conference, set to take place May 5-8, 2024, at the Beverly Hilton in Los Angeles. According to the announcement, Doug Drysdale, Cybin CEO, will appear on a panel entitled “Collaborating for Improved Mental Health,” on May 8, 2024, at 10:00 am PDT. “The Conference provides a meaningful platform to exchange ideas with global thought leaders and share our vision for transforming the treatment paradigm for mental health. With the recent…

Continue Reading

ThursdayApr 25, 2024 12:50 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Announces Celly Nu, Six+One Collaboration to Launch unbuzzd(TM)

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) today provided an update by way of a news release issued by Celly Nutrition Corp. (“Celly Nu”), and its launch of unbuzzd(TM), an innovative beverage product scientifically formulated from a proprietary blend of vitamins, minerals and botanical extracts designed to support the body’s natural processes for metabolizing alcohol and promoting alertness. Celly Nu has entered a strategic partnership with Six+One, a purpose-driven branding, advertising, and production agency based in New York City. Under the partnership, Six+One will significantly enhance the presence of the premier dietary supplement, unbuzzd, in preparation of the launch in…

Continue Reading

MondayApr 22, 2024 11:12 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Issues Update on Celly Nu’s Pending Launch of unbuzzd(TM)

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) today provided an update by way of a news release issued by Celly Nutrition Corp. (“Celly Nu”), and its launching of unbuzzd(TM), an innovative beverage product that is scientifically formulated from a proprietary blend of vitamins, minerals and botanical extracts designed to support the body’s natural processes for metabolizing alcohol and promoting alertness. According to the announcement, on April 22, 2024, Celly Nu announced a strategic partnership with BevSource, a St. Paul, Minnesota-based leading provider of beverage development, production and operations solutions. The partnership will assist with the production and distribution process of…

Continue Reading